Observational Study of Folate Receptor Alpha Prevalence in Ovarian Cancer, 1,000 Participants
Summary
The National Institutes of Health registered a new observational study (NCT07539844) to evaluate folate receptor alpha (FRa) prevalence in approximately 1,000 adult female participants with ovarian cancer across intercontinental countries. Archived tissue biopsies will be tested for FRa via immunohistochemistry, with data collected retrospectively while testing proceeds prospectively. No investigational drug will be administered; the study duration is approximately one year.
“Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected.”
What changed
NIH registered a new observational study on ClinicalTrials.gov (NCT07539844) titled 'Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental Countries.' The study will test archived tissue biopsies from approximately 1,000 participants for FRa expression via immunohistochemistry. It is retrospective in design (chart review) but testing will be performed prospectively.
Affected parties include clinical investigators conducting ovarian cancer research, pharmaceutical companies developing FRa-targeted therapies, and biotechnology firms with FRa-related drug pipelines. The study generates no compliance obligations but provides epidemiological data relevant to patient stratification for FRa-targeted treatments. No investigational product is administered.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Observational NCT07539844 Kind: OBSERVATIONAL Apr 20, 2026
Abstract
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer.
Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected. This is a retrospective study and testing will be performed prospectively on archived samples.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 1 Year.
There is no additional burden for participants in this trial.
Conditions: Ovarian Cancer
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.